<DOC>
	<DOC>NCT00540137</DOC>
	<brief_summary>The purpose of this study is to investigate the possibility of an association between changes in neurocognitive function, as measured by a computerised test battery, and the use of two different highly active antiretroviral therapy (HAART) regimens in treatment naïve HIV-1 infected subjects commencing antiretroviral therapy.</brief_summary>
	<brief_title>The CogNaive Study: Assessing Changes in Neurocognitive Function in Treatment Naïve HIV-1 Positive Subjects</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>HIV1 infected males or females Signed informed consent No previous antiretroviral treatment Males with CD4+ lymphocyte count &lt; 400 cells/ųL and females with CD4+ lymphocyte count &lt; 250 cells/ųL Susceptible to all currently licensed nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) Existing neurological disease Hepatitis B or hepatitis C coinfection Current history of major depression or psychosis Recent head injury Current alcohol abuse or drug dependence Active opportunistic infection or significant comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>Neurocognitive function</keyword>
	<keyword>Magnetic resonance spectroscopy</keyword>
	<keyword>HIV disease</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>